Whole genome methylation sequencing in blood from persons with mild cognitive impairment and dementia due to Alzheimer's disease identifies cognitive status
Open Access
- 1 January 2025
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (2)
Abstract
INTRODUCTION: Whole genome methylation sequencing (WGMS) in blood identifies differential DNA methylation in persons with late‐onset dementia due to Alzheimer's disease (AD) but has not been tested in persons with mild cognitive impairment (MCI). METHODS: We used WGMS to compare DNA methylation levels at 25,244,219 CpG loci in 382 blood samples from 99 persons with MCI, 109 with AD, and 174 who are cognitively unimpaired (CU). RESULTS: WGMS identified 9756 differentially methylated positions (DMPs) in persons with MCI, including 1743 differentially methylated genes encoding proteins in biological pathways related to synapse organization, dendrite development, and ion transport. A total of 447 DMPs exhibit progressively increasing or decreasing DNA methylation levels among CU, MCI, and AD that correspond to cognitive status. DISCUSSION: WGMS identifies DMPs in known and newly detected genes in blood from persons with MCI and AD that support blood DNA methylation levels can distinguish cognitive status. Highlights: Whole genome methylation levels in blood from 99 persons with mild cognitive impairment (MCI), 109 with Alzheimer's disease, and 174 who are cognitively unimpaired were analyzed. Nine thousand seven hundred fifty‐six differentially methylated positions (DMPs) were identified in MCI. One thousand seven hundred forty‐three genes comprise one or more DMPs in persons with MCI. Fifty‐eight DMPs and 392 differentially methylated genes are shared among the three pairwise comparisons. Four hundred forty‐seven DMPs exhibit progressive changes that correspond to cognitive status.Keywords
All Related Versions
Funding Information
- National Institutes of Health (R01AG066179)
- National Institutes of Health (R01AG021155)
- National Institutes of Health (R01AG027161)
- National Institutes of Health (P30AG062715)
- National Institutes of Health (HG003747)
- National Institutes of Health (S10OD025245)
- Alzheimer's Association (AARF19‐614533)
This publication has 56 references indexed in Scilit:
- Alterations in Blood Methylome as Potential Epigenetic Biomarker in Sporadic Parkinson's DiseaseAnnals of Neurology, 2024
- Insight into the genetic etiology of Alzheimer's disease: A comprehensive review of the role of rare variantsAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
- Non‐coding variants in MYH11, FZD3, and SORCS3 are associated with dementia in womenAlzheimer's & Dementia, 2020
- MAPT haplotype–stratified GWAS reveals differential association for AD risk variantsAlzheimer's & Dementia, 2020
- Differential methylation analysis for bisulfite sequencing using DSSQuantitative Biology, 2019
- The incidence of mild cognitive impairment: A systematic review and data synthesisAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2019
- Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene PromotersCell, 2016
- ggplot22016
- Mild Cognitive ImpairmentArchives of Neurology, 1999
- A wilcoxon‐type test for trendStatistics in Medicine, 1985